USP19 deficiency enhances T-cell-mediated antitumor immunity by promoting PD-L1 degradation in colorectal cancer
Authors:
Open Access
- 26 February 2025
- journal article
- Published by Elsevier in Pharmacological Research
- Vol. 214, 107668
Abstract
No abstract availableKeywords
Funding Information
- University of South China (221RGC003)
- Natural Science Foundation of Guangxi Zhuang Autonomous Region (2024GXNSFAA999020)
- Hunan Provincial Natural Science Foundation (2023JJ60049, 2024JJ6379)
- National Natural Science Foundation of China (32370777)
This publication has 46 references indexed in Scilit:
- EZH2 Inhibition Enhances PD‐L1 Protein Stability Through USP22‐Mediated Deubiquitination in Colorectal CancerAdvanced Science, 2024
- The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAPCancer Letters, 2023
- Deubiquitinase USP19 modulates apoptotic calcium release and endoplasmic reticulum stress by deubiquitinating BAG6 in triple negative breast cancerClinical and Translational Medicine, 2023
- USP19 Negatively Regulates p53 and Promotes Cervical Cancer ProgressionMolecular Biotechnology, 2023
- P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesisHepatology, 2023
- Deubiquitinase USP19 enhances phenylalanine hydroxylase protein stability and its enzymatic activityCell Biology and Toxicology, 2022
- Colorectal Cancer‐Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD‐L1 Expression in Tumor‐Associated MacrophagesAdvanced Science, 2022
- Single‐cell analyses reveal suppressive tumor microenvironment of human colorectal cancerClinical and Translational Medicine, 2021
- Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killingActa Pharmaceutica Sinica B, 2021
- Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5Acta Pharmaceutica Sinica B, 2020